The firm expects Danaher’s revenue growth to accelerate to 6% by 2027 amid bioprocess market recovery and end-market improvements.
RBC Capital resumed coverage of Danaher Corporation (DHR) with an Outperform rating and a $200 price target, citing a rebound in the bioprocess market and easing headwinds. The firm projects 6% revenue growth for Danaher by 2027, driven by sustained recovery and end-market strength.
Danaher reported Q1 2026 net earnings of $1.0 billion, or $1.45 per share, with revenues rising 3.5% year-over-year to $6.0 billion. Non-GAAP core revenue grew 0.5%, while operating cash flow reached $1.3 billion and free cash flow totaled $1.1 billion.
The company operates across diagnostics, biotechnology, life sciences, and environmental solutions, positioning it as a key player in medical and industrial markets.